A Phase 3 interventional study of rituximab [MabThera] in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 69 sites in Germany. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-07-29.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies testing rituximab in Arthritis, Rheumatoid — 5 open to participants now, 6 under way, 1 of them phase 3. Rituximab · Arthritis, Rheumatoid.
Among the 63 studies testing rituximab in Arthritis, Rheumatoid, this one is the 16th largest by enrollment, is one of 11 that started in 2006, is one of 27 in phase 3, and was the 46th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →5 of the 63 studies testing rituximab in Arthritis, Rheumatoid are open now, in 4 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Hospital, Strasbourg, France · Sites in France
Ages 18+
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
Ages 18+
University of Nebraska · Sites in United States
Ages 19+
Chinese SLE Treatment And Research Group · Sites in China
Ages 18–80
By country, each count listing its studies:
Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 13 · Phase 3 27 · Phase 4 14
First in 2001; this study’s year is marked. 11 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 302 is above the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 159 across the 63 interventional studies. Of the 57 that completed or were terminated, 37 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 63 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche: 2 open now, 2 under way, none of them phase 3. Of 214 finished, 139 (65%) have results posted.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 44th largest by enrollment of the 141 interventional ones that give a count, is one of 13 that started in 2006, is one of 85 in phase 3, and was the 185th registered.
Hoffmann-La Roche’s Arthritis, Rheumatoid studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 63 studies testing rituximab in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 219 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety of MabThera in patients with active rheumatoid arthritis who have had an inadequate response to one prior anti-TNF alpha inhibitor. MabThera-naive patients will be stratified into 3 arms, according to previous inadequate response to a)etanercept, b)infliximab or c)adalimumab. Patients will be treated with MabThera (1g infusion) on day 1 and day 15, and will continue their basic methotrexate therapy. The anticipated time on study treatment is 2+ years, and the target sample size is 100-500 individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: rituximab [MabThera]
1 g was given by intravenous infusion on Days 1 and 15
Change From Baseline to Week 24 in Disease Activity Score Based on 28-Joint Count (DAS28)
The DAS28 consists of swollen joint count (SJC) and tender joint count (TJC) measurements, the erythrocyte sedimentation rate (ESR) in millimeters per hour (mm/hr), and the Patient's Global Assessment of Disease Activity (participant-ated rheumatoid arthritis \[RA\] activity assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 less than or equal to (≤)3.2 equals (=) low disease activity, DAS28 greater than (\>)3.2 to 5.1 = moderate to high disease activity.
Time frame: Week 24
DAS28 Score
The DAS28 consists of SJC and TJC measurements, the ESR in mm/hr, and the Patient's Global Assessment of Disease Activity (participant-rated RA assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 ≤3.2 = low disease activity, DAS28 \>3.2 to 5.1 = moderate to high disease activity.
Time frame: Screening and Weeks 8, 16, and 24
Percentage of Participants With European League Against Rheumatism (EULAR) Response of Good or Moderate
The DAS28-based EULAR response criteria were used to measure individual responses as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders experienced a change from baseline of \>1.2 with a DAS28 score ≤3.2 and moderate responders experienced a change from baseline \>1.2 with DAS28 \>3.2 to ≤5.1 or a change from baseline \>0.6 to ≤1.2 with a DAS28 score of ≤5.1.
Time frame: Weeks 8, 16, and 24
Percentage of Participants With Low Disease Activity (DAS28 ≤3.2) at Week 24
Percentage of participants with low disease activity defined as DAS28 ≤3.2 at follow-up Week 24. The DAS28 consists of SJC and TJC measurements, the ESR in mm/hr, and the Patient's Global Assessment of Disease Activity (participant rated arthritis activity assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity).
Time frame: Week 24
Percentage of Participants Achieving Remission (DAS28 <2.6) at Week 24
Percentage of participants with remission defined as DAS28 \<2.6 at follow-up Week 24. The DAS28 consists of SJC and TJC measurements, the ESR in mm/hr, and the Patient's Global Assessment of Disease Activity (participant rated arthritis activity assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 ≤3.2 = low disease activity, DAS28 \>3.2 to 5.1 = moderate to high disease activity.
Time frame: Week 24
Percentage of Participants Achieving a Response By EULAR Category
Percentage of participants achieving a response by EULAR category, including 'moderate', 'good', or no response at follow-up Weeks 8, 16, and 24. The DAS28-based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders had a change from baseline \>1.2 with a DAS28 score ≤ 3.2; moderate responders had a change from baseline \>1.2 with a DAS28 score of \>3.2 to ≤5.1 or a change from baseline \>0.6 to ≤1.2 with a DAS28 score of ≤5.1; non-responders had a change from baseline ≤0.6 or change from baseline \>0.6 and ≤1.2 with a DAS28 score of \>5.1.
Time frame: Weeks 8, 16, and 24
Health Assessment Questionnaire - Disability Index (HAQ-DI) Score
The HAQ-DI score consists of questions referring to 8 categories: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common daily activities. For each of the categories, participants reported the amount of difficulty they had in performing 2 or 3 specific sub-category items. The standard disability score was calculated from the 8 categories by dividing the sum of the individual categories by the number of categories answered, yielding a score from 0 (without any difficulty) to 3 (unable to do).
Time frame: Screening and Weeks 8, 16, and 24
Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Score
The FACIT fatigue scale is base on a 13-item questionnaire to assess the therapy-induced fatigue. Participants were requested to score each question on a scale ranging from 0 (best) to 4 (worst). The scoring system of the FACIT fatigue scale adds up to a total scale ranging from 0 (best) to 52 (worst). The assessment was originally developed for chronic illnesses and is now validated for patients with rheumatoid arthritis (RA). The questionnaire was provided in a German translation.
Time frame: Screening and Weeks 8, 16, and 24
Short-Form 36 (SF-36) Physical Composite Scores (PCS) and Mental Composite Scores (MCS)
The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, bodily pain, physical role functioning, emotional role functioning, emotional well-being, social functioning, vitality, and general health perceptions. The 8 scales are further summarized to 2 distinct higher-ordered clusters: the physical and mental composite t-scores (PCS and MCS). The range for all 8 domains as well as for the composite t-scores is from 0 to 100 with 100 as best possible health status and 0 as worst health status.
Time frame: Screening and Weeks 8, 16, and 24
SF-36 Domain Scores
The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, bodily pain, physical role functioning, emotional role functioning, emotional well-being, social functioning, vitality, and general health perceptions. The 8 scales are further summarized to two distinct higher-ordered clusters: the physical and mental composite t-scores (PCS and MCS). The range for all 8 domains as well as for the composite t-scores is from 0 to 100 with 100 as best possible health status and 0 as worst health status.
Time frame: Screening and Weeks 8, 16, and 24
Percentage of Participants Achieving American College of Rheumatology (ACR) 20 Percent (%), 50% or 70% Response (ACR20/ACR50/ACR70)
ACR20/50/70 response: ≥20%, ≥50%, or ≥70% improvement, respectively, in tender or swollen joint counts and ≥20%, ≥50%, or ≥70% improvement, respectively, in 3 of the following 5 criteria: 1) Physician's Global Assessment of Disease Activity, 2) Patient's Global Assessment of Disease Activity, 3) Patient's Assessment of Pain, 4) participant assessment of functional disability via a HAQ-DI, and 5) C-reactive protein or ESR at each visit.
Time frame: Weeks 8, 16, and 24
Swollen Joint Count (SJC)
The 28 joints to be assessed for tenderness and swelling were shoulder, elbow, wrist, metacarpophalangeal (MCP) joints 1-5, proximal interphalangeal (PIP) joints 1-5, and knee on both sides of the body. The sum of swollen joints, each, ranged from 0 to 28 with 0 as best possible health status and 28 as worst health status.
Time frame: Screening and Weeks 8, 16, and 24
Tender Joint Count (TJC)
The 28 joints to be assessed for tenderness and swelling were shoulder, elbow, wrist, metacarpophalangeal (MCP) joints 1-5, proximal interphalangeal (PIP) joints 1-5, and knee on both sides of the body. The sum of tender joints ranged from 0 to 28 with 0 as best possible health status and 28 as worst health status.
Time frame: Screening and Weeks 8, 16, and 24
Physician's Global Assessment of Disease Activity
Physicians assessed the disease (RA) activity on a 100 mm horizontal VAS. The left-hand extreme of the line (0 mm) was described as "no disease activity" (symptom-free and no arthritis symptoms) and the right hand extreme (100 mm) as "maximum disease activity" (maximum arthritis disease activity).
Time frame: Screening and Weeks 8, 16, and 24
Patient's Assessment of Disease Activity
Participants were to assess the disease (RA) activity on a 100 mm horizontal VAS. The left-hand extreme of the line (0 mm) was described as "no disease activity" (symptom-free and no arthritis symptoms) and the right hand extreme (100 mm) as "maximum disease activity" (maximum arthritis disease activity).
Time frame: Screening and Weeks 8, 16, and 24
Patient's Assessment of Pain
Participants were to assess their current level of pain on a 100 mm horizontal VAS. The left-hand extreme of the line (0 mm) was described as "no pain" and the right-hand (100 mm) as "unbearable pain".
Time frame: Screening and Weeks 8, 16, and 24
C-Reactive Protein (CRP)
Mean CRP as measured as an acute phase reactant by mg per deciliter (mg/dL) at screening, Days 1 and 15, and Weeks 8, 16, and 24.
Time frame: Screening, Days 1 and 15, and Weeks 8, 16, and 24
Erythrocyte Sedimentation Rate (ESR)
Mean ESR, as an acute phase reactant, measured in mm/hr at screening, Days 1 and 15, and Weeks 8, 16, and 24.
Time frame: Screening, Days 1 and 15, and Weeks 8, 16, and 24
Rheumatoid Factor (RF)
Mean RF as measured by international unit per milliliter (IU/mL) at screening and Weeks 8, 16, and 24.
Time frame: Screening and Weeks 8, 16, and 24
| Milestone | Rituximab Plus Methotrexate (MTX) |
|---|---|
| Started | 302 |
| Completed | 273 |
| Not completed | 29 |
| Withdrew: Adverse event | 7 |
| Withdrew: Additional or changed therapy | 2 |
| Withdrew: Lack of efficacy | 9 |
| Withdrew: Protocol violation | 3 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Administrative problems | 1 |
| Withdrew: Inclusion into refirst | 3 |
| Withdrew: Other | 3 |
The DAS28 consists of swollen joint count (SJC) and tender joint count (TJC) measurements, the erythrocyte sedimentation rate (ESR) in millimeters per hour (mm/hr), and the Patient's Global Assessment of Disease Activity (participant-ated rheumatoid arthritis \[RA\] activity assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 less than or equal to (≤)3.2 equals (=) low disease activity, DAS28 greater than (\>)3.2 to 5.1 = moderate to high disease activity.
| scores on a scale | Rituximab + MTX |
|---|---|
| Change From Baseline to Week 24 in Disease Activity Score Based on 28-Joint Count (DAS28) | -1.56 ± 1.40 |
The DAS28 consists of SJC and TJC measurements, the ESR in mm/hr, and the Patient's Global Assessment of Disease Activity (participant-rated RA assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 ≤3.2 = low disease activity, DAS28 \>3.2 to 5.1 = moderate to high disease activity.
| scores on a scale | Rituximab + MTX |
|---|---|
| Screening (n=291) | 5.87 ± 1.05 |
| Week 8 (n=277) | 4.57 ± 1.30 |
| Week 16 (n=271) | 4.17 ± 1.31 |
| Week 24 (n=266) | 4.30 ± 1.47 |
The DAS28-based EULAR response criteria were used to measure individual responses as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders experienced a change from baseline of \>1.2 with a DAS28 score ≤3.2 and moderate responders experienced a change from baseline \>1.2 with DAS28 \>3.2 to ≤5.1 or a change from baseline \>0.6 to ≤1.2 with a DAS28 score of ≤5.1.
| percentage of participants | Rituximab + MTX |
|---|---|
| Week 8 (n=172) | 59.1 |
| Week 16 (n=198) | 68.0 |
| Week 24 (n=188) | 64.6 |
Percentage of participants with low disease activity defined as DAS28 ≤3.2 at follow-up Week 24. The DAS28 consists of SJC and TJC measurements, the ESR in mm/hr, and the Patient's Global Assessment of Disease Activity (participant rated arthritis activity assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity).
| percentage of participants | Rituximab + MTX |
|---|---|
| Percentage of Participants With Low Disease Activity (DAS28 ≤3.2) at Week 24 | 21.6 |
Percentage of participants with remission defined as DAS28 \<2.6 at follow-up Week 24. The DAS28 consists of SJC and TJC measurements, the ESR in mm/hr, and the Patient's Global Assessment of Disease Activity (participant rated arthritis activity assessment) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 ≤3.2 = low disease activity, DAS28 \>3.2 to 5.1 = moderate to high disease activity.
| percentage of participants | Rituximab + MTX |
|---|---|
| Percentage of Participants Achieving Remission (DAS28 <2.6) at Week 24 | 11.7 |
Percentage of participants achieving a response by EULAR category, including 'moderate', 'good', or no response at follow-up Weeks 8, 16, and 24. The DAS28-based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders had a change from baseline \>1.2 with a DAS28 score ≤ 3.2; moderate responders had a change from baseline \>1.2 with a DAS28 score of \>3.2 to ≤5.1 or a change from baseline \>0.6 to ≤1.2 with a DAS28 score of ≤5.1; non-responders had a change from baseline ≤0.6 or change from baseline \>0.6 and ≤1.2 with a DAS28 score of \>5.1.
| percentage of participants | Rituximab + MTX |
|---|---|
| Moderate response, Week 8 | 45.4 |
| Moderate response, Week 16 | 44.3 |
| Moderate response, Week 24 | 44.0 |
| Good response, Week 8 | 13.7 |
| Good response, Week 16 | 23.7 |
| Good response, Week 24 | 20.6 |
| No response, Week 8 | 36.1 |
| No response, Week 16 | 25.1 |
| No response, Week 24 | 26.8 |
The HAQ-DI score consists of questions referring to 8 categories: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and common daily activities. For each of the categories, participants reported the amount of difficulty they had in performing 2 or 3 specific sub-category items. The standard disability score was calculated from the 8 categories by dividing the sum of the individual categories by the number of categories answered, yielding a score from 0 (without any difficulty) to 3 (unable to do).
| scores on a scale | Rituximab + MTX |
|---|---|
| Screening (n=288) | 1.60 ± 0.67 |
| Week 8 (n=286) | 1.43 ± 0.66 |
| Week 16 (n=276) | 1.33 ± 0.66 |
| Week 24 (n=269) | 1.32 ± 0.70 |
The FACIT fatigue scale is base on a 13-item questionnaire to assess the therapy-induced fatigue. Participants were requested to score each question on a scale ranging from 0 (best) to 4 (worst). The scoring system of the FACIT fatigue scale adds up to a total scale ranging from 0 (best) to 52 (worst). The assessment was originally developed for chronic illnesses and is now validated for patients with rheumatoid arthritis (RA). The questionnaire was provided in a German translation.
| scores on a scale | Rituximab + MTX |
|---|---|
| Screening (n=286) | 23.81 ± 11.35 |
| Week 8 (n=282) | 20.87 ± 11.14 |
| Week 16 (n=272) | 18.92 ± 11.46 |
| Week 24 (n=262) | 18.53 ± 11.48 |
The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, bodily pain, physical role functioning, emotional role functioning, emotional well-being, social functioning, vitality, and general health perceptions. The 8 scales are further summarized to 2 distinct higher-ordered clusters: the physical and mental composite t-scores (PCS and MCS). The range for all 8 domains as well as for the composite t-scores is from 0 to 100 with 100 as best possible health status and 0 as worst health status.
| scores on a scale | Rituximab + MTX |
|---|---|
| PCS, Screening (n=287) | 30.97 ± 8.14 |
| PCS, Week 8 (n=279) | 34.24 ± 8.56 |
| PCS, Week 16 (n=270) | 35.92 ± 8.43 |
| PCS, Week 24 (n=264) | 36.36 ± 9.00 |
| MCS, Screening (n=287) | 40.88 ± 13.16 |
| MCS, Week 8 (n=279) | 43.50 ± 12.31 |
| MCS, Week 16 (n=270) | 45.17 ± 12.32 |
| MCS, Week 24 (n=264) | 44.92 ± 13.13 |
The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, bodily pain, physical role functioning, emotional role functioning, emotional well-being, social functioning, vitality, and general health perceptions. The 8 scales are further summarized to two distinct higher-ordered clusters: the physical and mental composite t-scores (PCS and MCS). The range for all 8 domains as well as for the composite t-scores is from 0 to 100 with 100 as best possible health status and 0 as worst health status.
| scores on a scale | Rituximab + MTX |
|---|---|
| Physical functioning, Screening (n=289) | 39.04 ± 24.83 |
| Physical functioning, Week 8 (n=284) | 43.60 ± 24.50 |
| Physical functioning, Week 16 (n=276) | 44.64 ± 25.13 |
| Physical functioning, Week 24 (n=268) | 47.37 ± 26.19 |
| Bodily pain, Screening (n=290) | 25.94 ± 17.75 |
| Bodily pain, Week 8 (n=285) | 37.24 ± 19.00 |
| Bodily pain, Week 16 (n=275) | 44.25 ± 21.60 |
| Bodily pain, Week 24 (n=267) | 44.06 ± 22.13 |
| Physical role functioning, Screening (n=290) | 35.11 ± 22.42 |
| Physical role functioning, Week 8 (n=284) | 43.72 ± 23.95 |
| Physical role functioning, Week 16 (n=276) | 48.37 ± 23.48 |
| Physical role functioning, Week 24 (n=269) | 49.63 ± 25.04 |
| Emotional role functioning, Screening (n=289) | 52.77 ± 31.23 |
| Emotional role functioning, Week 8 (n=282) | 59.13 ± 27.26 |
| Emotional role functioning, Week 16 (n=276) | 62.41 ± 27.57 |
| Emotional role functioning, Week 24 (n=268) | 61.29 ± 27.98 |
| Emotional well-being, Screening (n=289) | 56.11 ± 20.07 |
| Emotional well-being, Week 8 (n=285) | 60.43 ± 19.82 |
| Emotional well-being, Week 16 (n=276) | 63.02 ± 20.51 |
| Emotional well-being, Week 24 (n=268) | 64.03 ± 21.03 |
| Social functioning, Screening (n=291) | 56.62 ± 27.23 |
| Social functioning, Week 8 (n=285) | 64.04 ± 25.87 |
| Social functioning, Week 16 (n=277) | 65.93 ± 26.10 |
| Social functioning, Week 24 (n=270) | 66.99 ± 28.11 |
| Vitality, Screening (n=290) | 38.49 ± 19.41 |
| Vitality, Week 8 (n=285) | 43.42 ± 19.76 |
| Vitality, Week 16 (n=276) | 48.25 ± 20.32 |
| Vitality, Week 24 (n=268) | 48.22 ± 20.75 |
| General health perceptions, Screening (n=291) | 39.14 ± 14.49 |
| General health perceptions, Week 8 (n=285) | 45.61 ± 15.06 |
| General health perceptions, Week 16 (n=272) | 48.54 ± 17.16 |
| General health perceptions, Week 24 (n=269) | 48.30 ± 17.53 |
ACR20/50/70 response: ≥20%, ≥50%, or ≥70% improvement, respectively, in tender or swollen joint counts and ≥20%, ≥50%, or ≥70% improvement, respectively, in 3 of the following 5 criteria: 1) Physician's Global Assessment of Disease Activity, 2) Patient's Global Assessment of Disease Activity, 3) Patient's Assessment of Pain, 4) participant assessment of functional disability via a HAQ-DI, and 5) C-reactive protein or ESR at each visit.
| percentage of participants | Rituximab + MTX |
|---|---|
| ACR20, Week 8 | 38.8 |
| ACR20, Week 16 | 47.8 |
| ACR20, Week 24 | 46.4 |
| ACR50, Week 8 | 13.7 |
| ACR50, Week 16 | 19.9 |
| ACR50, Week 24 | 24.4 |
| ACR70, Week 8 | 2.7 |
| ACR70, Week 16 | 8.2 |
| ACR70, Week 24 | 10.0 |
The 28 joints to be assessed for tenderness and swelling were shoulder, elbow, wrist, metacarpophalangeal (MCP) joints 1-5, proximal interphalangeal (PIP) joints 1-5, and knee on both sides of the body. The sum of swollen joints, each, ranged from 0 to 28 with 0 as best possible health status and 28 as worst health status.
| swollen joints | Rituximab + MTX |
|---|---|
| Screening (n=291) | 10.01 ± 5.34 |
| Week 8 (n=288) | 5.16 ± 4.73 |
| Week 16 (n=282) | 4.22 ± 4.07 |
| Week 24 (n=272) | 4.70 ± 4.67 |
The 28 joints to be assessed for tenderness and swelling were shoulder, elbow, wrist, metacarpophalangeal (MCP) joints 1-5, proximal interphalangeal (PIP) joints 1-5, and knee on both sides of the body. The sum of tender joints ranged from 0 to 28 with 0 as best possible health status and 28 as worst health status.
| tender joints | Rituximab + MTX |
|---|---|
| Screening (n=291) | 12.62 ± 6.31 |
| Week 8 (n=288) | 7.53 ± 6.71 |
| Week 16 (n=282) | 6.04 ± 6.31 |
| Week 24 (n=272) | 6.41 ± 6.37 |
Physicians assessed the disease (RA) activity on a 100 mm horizontal VAS. The left-hand extreme of the line (0 mm) was described as "no disease activity" (symptom-free and no arthritis symptoms) and the right hand extreme (100 mm) as "maximum disease activity" (maximum arthritis disease activity).
| mm | Rituximab + MTX |
|---|---|
| Screening (n=291) | 63.99 ± 15.40 |
| Week 8 (n=286) | 39.20 ± 19.85 |
| Week 16 (n=280) | 33.03 ± 19.96 |
| Week 24 (n=271) | 35.75 ± 23.92 |
Participants were to assess the disease (RA) activity on a 100 mm horizontal VAS. The left-hand extreme of the line (0 mm) was described as "no disease activity" (symptom-free and no arthritis symptoms) and the right hand extreme (100 mm) as "maximum disease activity" (maximum arthritis disease activity).
| mm | Rituximab + MTX |
|---|---|
| Screening (n=291) | 63.49 ± 20.88 |
| Week 8 (n=286) | 46.19 ± 23.51 |
| Week 16 (n=278) | 41.25 ± 24.99 |
| Week 24 (n=270) | 41.47 ± 25.50 |
Participants were to assess their current level of pain on a 100 mm horizontal VAS. The left-hand extreme of the line (0 mm) was described as "no pain" and the right-hand (100 mm) as "unbearable pain".
| mm | Rituximab + MTX |
|---|---|
| Screening (n=291) | 62.78 ± 20.80 |
| Week 8 (n=287) | 47.30 ± 23.26 |
| Week 16 (n=276) | 42.11 ± 25.14 |
| Week 24 (n=269) | 41.76 ± 25.52 |
Mean CRP as measured as an acute phase reactant by mg per deciliter (mg/dL) at screening, Days 1 and 15, and Weeks 8, 16, and 24.
| mg/dL | Rituximab + MTX |
|---|---|
| Screening (n=289) | 1.82 ± 2.35 |
| Day 1 (n=233) | 1.60 ± 1.96 |
| Day 15 (n=286) | 1.81 ± 2.27 |
| Week 8 (n=283) | 1.31 ± 1.44 |
| Week 16 (n=281) | 1.21 ± 1.65 |
| Week 24 (n=269) | 1.30 ± 1.77 |
Mean ESR, as an acute phase reactant, measured in mm/hr at screening, Days 1 and 15, and Weeks 8, 16, and 24.
| mm/hr | Rituximab + MTX |
|---|---|
| Screening (n=291) | 30.20 ± 20.56 |
| Day 1 (n=225) | 28.07 ± 19.51 |
| Day 15 (n=277) | 30.61 ± 21.46 |
| Week 8 (n=279) | 24.85 ± 16.68 |
| Week 16 (n=276) | 22.28 ± 16.58 |
| Week 24 (n=268) | 23.64 ± 17.36 |
Mean RF as measured by international unit per milliliter (IU/mL) at screening and Weeks 8, 16, and 24.
| IU/mL | Rituximab + MTX |
|---|---|
| Screening (n=279) | 178.23 ± 352.61 |
| Week 8 (n=255) | 109.84 ± 213.32 |
| Week 16 (n=259) | 88.22 ± 174.99 |
| Week 24 (n=258) | 87.52 ± 187.94 |
Collected over From first dose of study drug up to 24 weeks of follow up.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rituximab + MTX | — | 36/302 (11.9%) | 62/302 (20.5%) |
| Event | Rituximab + MTX |
|---|---|
| Musculoskeletal and connective tissue disordersMusculoskeletal and connective tissue disorders | 9/302 |
| Infections and infestationsInfections and infestations | 7/302 |
| Injury, poisoning and procedural complicationsInjury, poisoning and procedural complications | 7/302 |
| Gastrointestinal disordersGastrointestinal disorders | 5/302 |
| Cardiac disordersCardiac disorders | 3/302 |
| General disorders and administration site conditionsGeneral disorders | 2/302 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps)Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/302 |
| Nervous system disordersNervous system disorders | 2/302 |
| Ear and labyrinth disordersEar and labyrinth disorders | 1/302 |
| Endocrine disordersEndocrine disorders | 1/302 |
| Event | Rituximab + MTX |
|---|---|
| NasopharyngitisInfections and infestations | 37/302 |
| CoughRespiratory, thoracic and mediastinal disorders | 19/302 |
| HypertensionVascular disorders | 17/302 |
Safety population: all participants who received at least 1 dose of trial medication and had at least 1 safety follow-up.
| Age, Continuous(years) | Rituximab + MTX |
|---|---|
| Mean | 54.4 ± 18.77 |
| Sex: Female, Male(Participants) | Rituximab + MTX |
|---|---|
| Female | 228 |
| Male | 74 |
| Race/Ethnicity, Customized(participants) | Rituximab + MTX |
|---|---|
| Caucasian | 301 |
| Asian | 1 |
The record gives a start of Nov 2006, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2015, 4 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rituximab